A Shire logo is seen outside their offices in Dublin, Ireland, April 25, 2018. REUTERS/Clodagh Kilcoyne
May 8, 2018
LONDON (Reuters) – Takeda Pharma <4502.T> agreed to buy London-listed Shire <SHP.L> for 45.3 billion pounds ($61.50 billion) on Tuesday after the Japanese company raised the amount of cash in its offer to $30.33 to secure a recommendation.
Shire investors will receive $30.33 in cash and either 0.839 new Takeda shares or 1.678 Takeda ADSs for each share, the companies said, valuing the offer at 48.17 pounds a share based on the latest price and exchange rate.
Takeda expects substantial cost synergies of at least $1.4 billion.
The deal – assuming it wins backing of shareholders – will be the largest overseas acquisition by a Japanese company and propel Takeda, led by Frenchman Christophe Weber, into the top ranks of global drugmakers.
“Together, we will be a leader in providing targeted treatments in gastroenterology, neuroscience, oncology, rare diseases and plasma-derived therapies,” he said.
The tie-up is also one of the largest ever in the pharmaceuticals sector, crowning a hectic few months of deal-making as large players look to improve their pipelines.
Shire said last month it would be willing to recommend an offer from Takeda after it rejected four previous approaches.
Shire shareholders will own about half of the combined group after the deal.
(Reporting by Paul Sandle and Ben Hirschler; editing by Kate Holton)
